ZECUITY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZECUITY (ZECUITY).
Selegiline is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). It inhibits the breakdown of dopamine by MAO-B, increasing dopaminergic activity in the brain.
| Metabolism | Hepatic metabolism primarily via MAO-B inhibition and further metabolism to N-desmethylselegiline, amphetamine, and methamphetamine. CYP450 enzymes not significantly involved. |
| Excretion | Sumatriptan is primarily eliminated by metabolism followed by renal excretion of metabolites. Approximately 60% of a dose is recovered in urine (22% as unchanged sumatriptan, 38% as metabolites) and 40% in feces (primarily metabolites). |
| Half-life | The terminal elimination half-life of sumatriptan is approximately 2 hours (range 1–4 hours). Due to this short half-life, a second dose may be considered if migraine recurs after initial relief, but no more than two doses in 24 hours via the same route. |
| Protein binding | Sumatriptan is approximately 14–21% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | The volume of distribution is approximately 2.4–3.0 L/kg, indicating extensive distribution into tissues beyond plasma. |
| Bioavailability | Iontophoretic transdermal system (Zecuity): Absolute bioavailability is approximately 99% of the delivered dose, as sumatriptan is delivered directly into the systemic circulation. The system delivers 6.5 mg of sumatriptan over 4 hours. |
| Onset of Action | Iontophoretic transdermal system (Zecuity): Onset of relief typically occurs within 30–60 minutes after application; the system delivers 6.5 mg over 4 hours. |
| Duration of Action | Duration of effect is typically 4–6 hours, consistent with the infusion profile of the patch. Patients may experience recurrence after this period and may need a second dose (if allowed). |
| Molecular Weight | 295.4 |
Apply one 1.3 mg/24 hour transdermal system to a clean, dry, hairless area of the upper arm or thigh for 24 hours; can be repeated at 24-hour intervals for up to 12 weeks.
| Dosage form | SYSTEM |
| Renal impairment | No specific dose adjustment recommended for GFR ≥30 mL/min; contraindicated in end-stage renal disease (GFR <15 mL/min) and in patients requiring dialysis. |
| Liver impairment | Contraindicated in Child-Pugh Class C (severe hepatic impairment); use with caution in Child-Pugh Class A or B, with no specific dose adjustment recommended in mild to moderate impairment. |
| Pediatric use | Not approved for use in pediatric patients (safety and effectiveness not established). |
| Geriatric use | No specific dose adjustment recommended; however, elderly patients may be more sensitive to anticholinergic effects; use with caution and monitor for adverse effects. |
| 1st trimester | Avoid; teratogenic risk based on animal studies and limited human data. May cause fetal harm. |
| 2nd trimester | Avoid; risk of fetal adverse effects including reduced fetal growth and potential for withdrawal syndrome. |
| 3rd trimester | Avoid; risk of neonatal withdrawal syndrome and respiratory depression. |
Clinical note
Comprehensive clinical and safety monograph for ZECUITY (ZECUITY).
| Placental transfer | Zecuity (sumatriptan) is known to cross the placenta; detectable in cord blood and amniotic fluid. |
| Breastfeeding | Not recommended due to potential for serious adverse reactions in nursing infants, including sedation and withdrawal symptoms. Discontinue drug or nursing. |
| Lactation Rating |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. ZECUITY is not approved for use in pediatric patients.
| Serious Effects |
History of ischemic heart disease or coronary artery vasospasmUncontrolled hypertensionHemiplegic or basilar migraineUse within 24 hours of other triptans or ergotamine-containing medicationsSevere hepatic impairmentHypersensitivity to sumatriptan or any component
| Precautions | Serotonin syndrome when used with other serotonergic drugs, Tyramine-induced hypertensive crisis if dietary tyramine restrictions are not followed (especially with higher doses), Activation of mania/hypomania in bipolar disorder, Seizures in patients with history of seizure disorders, Suicidality monitoring in young adults and children |
| Food/Dietary | No specific food interactions have been reported with ZECUITY. However, patients should avoid alcohol, as it can worsen migraine symptoms or increase drowsiness. |
Loading safety data…
| L5 - Contraindicated |
| Teratogenic Risk | Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal abnormalities; human data limited. Second/third trimester: Risk of neonatal withdrawal (irritability, hypertonia, tremors) and persistent pulmonary hypertension of the newborn (PPHN) with late use. Consider risks vs benefits. |
| Fetal Monitoring | Monitor fetal growth and amniotic fluid index via ultrasound if used chronically; assess for neonatal withdrawal signs after delivery; monitor maternal blood pressure and ECG in patients with cardiovascular risk factors. |
| Fertility Effects | No evidence of adverse effects on fertility in animal studies; no human data. Sumatriptan and naproxen sodium may affect ovulation (NSAIDs) and spermatogenesis (sumatriptan in animals). |
| Clinical Pearls | ZECUITY (sumatriptan iontophoretic transdermal system) delivers sumatriptan via low-level electrical current. Apply to a site with intact skin, typically upper arm or thigh, avoiding areas with hair, scars, or tattoos. Do not cut or damage the system. Remove before MRI or electrical procedures. Onset of headache relief is slower than oral or injectable sumatriptan but preferred for patients with nausea or vomiting. Do not use within 24 hours of other triptans or ergotamines. Contraindicated in hemiplegic or basilar migraine, ischemic heart disease, uncontrolled hypertension, or within 24 hours of MAO-A inhibitors. |
| Patient Advice | Apply ZECUITY to a clean, dry area on the upper arm or thigh, avoiding cuts, scars, or irritated skin. · Do not cut, tear, or modify the patch; activate it by pressing the button when instructed. · The patch delivers medication over 4 hours; you may feel a tingling or warm sensation during use. · Remove the patch after 4 hours or if you experience skin irritation; do not reuse. · Do not use more than one patch in a 24-hour period or from different application sites. · Seek emergency care if you experience chest pain, shortness of breath, irregular heartbeat, or severe headache. · Avoid driving or operating machinery until you know how ZECUITY affects you, as dizziness or drowsiness may occur. · Store at room temperature; keep out of reach of children; discard used patches properly. |